drugset / Trial / NCT03059797
Study of Anlotinib in Patients With Small Cell Lung Cancer (ALTER1202)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To compare the effects and safety of Anlotinib with placebo in patients with small cell lung cancer(SCLC).
Timeline
- Start
- 2017-03-27
- Primary completion
- 2018-06-30
- Completion
- 2019-05-06
Outcome
Met primary endpoint
paper The median PFS was significantly longer in the anlotinib group compared with the placebo group PMID 34006926 ↗
paper hazard ratio (HR) 0.19 [95% CI, 0.12-0.32], p < 0.0001 PMID 34006926 ↗
Publications
- Gong J, Wan Q, Shang J, Qian X, Su D, Sun Z, Liu G. Cost-Effectiveness Analysis of Anlotinib as Third- or Further-Line Treatment for Relapsed Small Cell Lung Cancer (SCLC) in China. Adv Ther. 2021 Oct;38(10):5116-5126. doi: 10.1007/s12325-021-01889-2. Epub 2021 Aug 21.
- Zhang C, Wang J, Wang X, Meng Z, Cheng Y, Li K. Peripheral blood indices to predict PFS/OS with anlotinib as a subsequent treatment in advanced small-cell lung cancer. Cancer Biol Med. 2021 Jul 24;19(8):1249-58. doi: 10.20892/j.issn.2095-3941.2020.0727.
- Cheng Y, Wang Q, Li K, Shi J, Liu Y, Wu L, Han B, Chen G, He J, Wang J, Lou D, Yu H, Wang S, Qin H, Li X. Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study. Br J Cancer. 2021 Aug;125(3):366-371. doi: 10.1038/s41416-021-01356-3. Epub 2021 May 18.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | 12 mg | Oral |